Table 4.
Baseline characteristics of patients with and without cirrhosis or high NFS.
| Variable | Advanced fibrosis or cirrhosis (n = 88) | No advanced fibrosis or cirrhosis (n = 93) | p value |
|---|---|---|---|
| Demographics | |||
| Age | 71.1 (61–79) | 66 (56–75) | 0.005 |
| Male sex | 47 (53.4%) | 59 (63.4%) | 0.17 |
| BMI (kg/m2) | 37.4 (30.1–44.6) | 33.6 (27.5–39.7) | 0.008 |
| Clinical characteristics | |||
| Hypertension | 74 (84.1%) | 73 (78.5%) | 0.33 |
| Coronary artery disease | 39 (44.3%) | 36 (38.7%) | 0.44 |
| Diabetes mellitus | 52 (59.1%) | 35 (37.6%) | 0.004 |
| Atrial fibrillation | 51 (57.9%) | 36 (38.7%) | 0.01 |
| Dyslipidemia | 58 (65.9%) | 61 (65.5%) | 0.96 |
| Chronic kidney disease | 53 (60.2%) | 43 (46.2%) | 0.05 |
| Heart failure severity | |||
| NYHA class III–IV | 58 (62.3%) | 51 (56.0%) | 0.07 |
| BNP | 143 (64.5–299.5) | 102 (34–212) | 0.06 |
| Echocardiography | |||
| Ejection fraction | 60 (60–65) | 60 (60–65) | 0.77 |
| IVS | 11 (10–13) | 10 (9–12) | 0.06 |
| Left atrial diameter | 47 (44–54) | 43 (38–49) | 0.001 |
| RVSP | 50 (38–59) | 43 (33–58) | 0.25 |
| E/A ratio | 1.25 (1.0–1.6) | 1.1 (0.8–2.0) | 0.73 |
| Diastolic dysfunction Grade ≥ 2 | 21 (53.8%) | 17 (32.7%) | 0.04 |
| RV systolic dysfunction | 17 (20.7%) | 9 (10.5%) | 0.06 |
| Metabolic evaluation | |||
| Total cholesterol | 153.5 (119.5–176.5) | 160 (134–187.5) | 0.13 |
| Triglycerides | 113 (89.5–162) | 129 (86–178) | 0.58 |
| HDL | 44.5 (36–56.5) | 47 (39–60.5) | 0.41 |
| LDL | 70 (57.5–91.5) | 82 (60.5–105) | 0.06 |
| A1c | 6.3 (5.8–7.6) | 6.2 (5.6–7.4) | 0.46 |
| Hepatic evaluation | |||
| INR | 1.1 (1–1.5) | 1 (0.97–1.2) | 0.02 |
| Total bilirubin | 0.6 (0.4–0.9) | 0.5 (0.3–0.7) | 0.001 |
Bolded values indicate results that are statistically significant